Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference
August 29 2018 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, today announced that
Patrick J. McEnany, Chief Executive Officer, and Steven Miller,
Ph.D., Chief Operating Officer and Chief Scientific Officer, will
be presenting at Rodman & Renshaw’s 20th Annual Global
Investment Conference, which is being held on September 4-6, 2018
at the St. Regis New York Hotel in New York City.
The presentation will occur on Wednesday,
September 5th at 1:45 PM ET. The presentation materials will
be posted at www.catalystpharma.com in the Investor section under
Events and Presentations.
About Catalyst
Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular
and neurological diseases, including Lambert-Eaton myasthenic
syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK
antibody positive myasthenia gravis, and spinal muscular atrophy
(SMA) type 3. Firdapse® (amifampridine phosphate) has received
Breakthrough Therapy Designation from the U.S. Food and Drug
Administration (FDA) for the treatment of LEMS and Orphan Drug
Designation for LEMS, CMS and myasthenia gravis. Firdapse is the
first and only approved drug in Europe for symptomatic treatment in
adults with LEMS.
Catalyst is also developing CPP-115 to treat
refractory infantile spasms. CPP-115 has been granted U.S. Orphan
Drug Designation for the treatment of infantile spasms by the FDA
and has been granted E.U. Orphan Medicinal Product Designation for
the treatment of West syndrome by the European Commission. In
addition, Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including (i) whether Firdapse will ever be
approved for commercialization, (ii) whether, even if Firdapse is
approved for commercialization, Catalyst will be successful in
commercializing Firdapse, (iii) whether Catalyst will be the first
company to receive an approval for amifampridine (3,4-DAP), giving
it 5-year marketing exclusivity for its product, and (iv) those
other factors described in Catalyst's Annual Report on Form 10-K
for the fiscal year 2017 and its other filings with the U.S.
Securities and Exchange Commission (SEC), could adversely affect
Catalyst. Copies of Catalyst's filings with the SEC are available
from the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024